Refreshed Drug Discount Dispute Process to Face Wave of Claims

A revamped dispute resolution process for price fights between drugmakers and health-care providers is likely to spur an influx of claims after a final rule revised the procedure to be more accessible.

The HHS’s Health Resources and Services Administration’s new swing at an administrative dispute resolution (ADR) process for the federal 340B drug discount program seeks to lay out an administratively feasible and timely process for manufacturers and health-care providers. The revised action comes after the Biden administration pulled the plug on a previous resolution process put forth by the Trump administration.

The 340B program requires manufacturers participating in Medicaid ...